This email will cover the following topics:

• Reporting Out-Of-Range Temperatures Policy Shift
• Updated Adult and Childhood Availability Tables
• MenACWY Policy Update
• QAA Site Visit Scheduling
• Respiratory Vaccine Reminders
• Friendly Reminders

Effective July 1st, provider sites are no longer required to report minor temperature deviations to the Vaccine Program. However, if an out-of-range temperature lasts a cumulative 30 minutes (within a 24-hour period) sites must contact the Vaccine Program immediately via the submission of a TempX form in the MIIS, as this is still considered a temperature excursion. Shorter out-of-range temperatures do not require reporting to the Vaccine Program, as viability data indicates that the vaccines will remain viable, as described in the tables below.

The Childhood Availability Table has been updated to resolve an oversight regarding the use of state-supplied Men-B vaccine. State-supplied Men-B vaccine can be administered to all high-risk pediatric patients, not just as part of a Men-B outbreak response. Whilst this is not a new policy for state-supplied Men-B vaccine, the Childhood Availability Table was updated to correct a previous typo regarding eligibility.

The Adult Availability Table has been updated to reflect the recent changes in vaccine administration policy regarding MenACWY administration at public provider sites, as described in the section below. Both updated Availability Tables are currently available on the Vaccine Management website.

Effective July 1^st, 2025, state-supplied Meningococcal A,C,W,Y vaccines are able to be administered at public provider sites (community health centers, local health departments) to uninsured and underinsured adult patients aged 19-20 years old that require the vaccine to fulfill Massachusetts school immunization requirements. This shift in MenACWY administration policy is aimed at bridging a longstanding gap between school vaccination requirements and state-supplied vaccine availability for uninsured and underinsured adults.

Any patient uninsured or underinsured patient aged 19-20 years old who does not require the vaccine to meet school requirements, must still receive a privately purchased dose of MenACWY, even if seen at a public site. Additionally, any patient above the age of 20, regardless of insurance status, must still be given a privately purchased dose of MenACWY.

Vaccine Program Quality Assurance Analysts (QAAs) will begin reaching out to provider sites to schedule Compliance Site Visits starting in mid-July. As a reminder, all sites that are fully enrolled in the Vaccine Program are required to have a Compliance Site Visit conducted every 2 years. If contacted, please work with your assigned QAA to get the site visit scheduled. Delays in scheduling Compliance Site Visits may impact your site's ability to order state-supplied vaccine moving forward.

Unannounced Site Visits will also begin again, starting in mid-July. By enrolling in the Vaccine Program, your site has agreed to potentially be visited for an unannounced visit. Please work with the QAA staff member assigned for the unannounced visit, so that the visit can be completed in a timely manner, with the least interruptions to your site's day-to-day functionality.

Flu Vaccines:

• All state-supplied flu doses have expired on June 30, 2025.
• Any doses that remain in your inventory at this time will need to be returned, via a submission of a storage and handling issue in the MIIS.
• State-supplied trivalent flu vaccines for the 2025-2026 Respiratory Season will be available to order in the following months.

COVID-19 Vaccines:

• State-supplied 2024-2025 formulations of Pfizer and Moderna COVID-19 vaccines remain orderable via the MIIS.
• It is anticipated that COVID-19 vaccines in some capacity will remain available to order until the 2025-2026 formulations are released in the Fall.

Nirsevimab Reminder:

• Clinical guidance recommends halting nirsevimab administration until Fall 2025.
• Providers who have doses remaining in inventory should continue to store the doses in the appropriate storage conditions. There is a chance some nirsevimab lots receive shelf-life extensions before they expire.
• Nirsevimab doses left over from this season should be administered before any doses from the 2025-2026 season are administered.

• Email sensitech.support@carrier.com with any SmartView/Berlinger DDL issues.
• When submitting Merck packing slips (ProQuad/Varivax), ensure the shipped quantity is equal to the order quantity for both the vaccine and diluent (may be more than a single packing slip).
• If the packing slip for the state-supplied Merck frozen vaccines is listed as "Sold To: Mass Dept of Public Health- CDC VFC", these packing slips must be signed, dated and emailed to the Vaccine Unit as soon as possible upon receipt.
• Refer to the Vaccine Management Contact List and Stability Calculator reference page for updated phone numbers and websites for vaccine manufacturers.
• Always include PIN/Site Number, name and phone number when contacting the Vaccine Management Unit.